---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-23-000030"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:20:40.071507+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Travere reports positive Phase 1/2 COMPOSE Cohort 6 data for pegtibatinase in HCU

## Summary
- Pegtibatinase 2.5 mg/kg twice weekly reduced total homocysteine (tHcy) by mean 67.1% vs placebo increase of 0.6%.
- All 4 treated patients achieved mean tHcy below 100 µM threshold; one patient with low baseline achieved normalization.
- No treatment-related serious adverse events, anaphylaxis, or discontinuations in cohort 6.
- Methionine reduced and cystathionine elevated, consistent with desired CBS enzyme activity.
- Company plans to initiate Phase 3 program by end of 2023 after regulatory engagement.

## SEC filing metadata
- accession: 0001438533-23-000030
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000030/0001438533-23-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000030/tvtx-20230531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-23-000030
- JSON: https://secwatch.observer/filing/0001438533-23-000030.json
- Plain text: https://secwatch.observer/filing/0001438533-23-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.